Entyvio (Vedolizumab) Patent Expiration, LOE Window & CMS Spending

Entyvio (Vedolizumab) by Takeda: Biologic BLA (Purple Book Regime), 0 AB generics, $349.4M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTakeda
FDA Application & PathwayB125476 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$349.4M
2024 Medicare Part D Spend$129.2M
2024 Medicaid Spend$220.1M
Reported Wholesale Price Change (CA SB 17)5 WAC filings (max 23.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.